Clinical Trial

Efficacy of Dextromethorphan-Bupropion Versus SSRIs in the Treatment of Major Depressive Disorder

Completed
View on ClinicalTrials.gov →
Summary
The study aims to compare the antidepressant effects of a dextromethorphan-bupropion combination versus standard SSRI therapy in adult patients with major depressive disorder. Participants will be randomized into two groups: one receiving dextromethorphan-bupropion and the other receiving an SSRI (e.g., sertraline or escitalopram). Treatment will last for 6 weeks, with assessments at baseline and study completion. The primary outcome will be the remission rate measured by a validated depression rating scale. Secondary outcomes include change in depressive symptoms severity and safety/tolerability measures.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-26; most recent amendment 2026-05-03.
Status change: Active, Not Recruiting → Completed 2026-05-03
Status change: Recruiting → Active, Not Recruiting 2025-07-04
Status change: Not Yet Recruiting → Recruiting 2025-05-05
Trial Details
NCT Number NCT06957223
Lead Sponsor Asad Ullah Jan
Collaborators: Combined Military Hospital Nowshera
Conditions Major Depressive Disorder (MDD)
Enrollment 80 participants
Start Date 2025-05-06
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-07